Solazyme is Trading Below Cash; Should You Buy?

When it comes to traditional biotech investing — that is, biotech stocks in healthcare — it’s not uncommon for a company to fall dramatically after a negative outcome from a binary event, such as a failed clinical trial. In some instances, development-stage companies with no products on the market and few revenue streams can see their market value fall below […]